A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis

The PIEDA Study: A Phase 3b Investigation of Erythropoietin Drugs Using A Specified Dosing Algorithm: A Randomized Open Label Dosing Study in Adult Chronic Kidney Disease Subjects on Hemodialysis

Category & Conditions:
Cardiovasular Diseases and Conditions
Medicine:
RETACRIT INJECTION(EPOETIN ALFA-EPBX)
ClinicalTrials.gov Identifier (NCT):
Protocol ID:
C3461008
Open Plain Language Summary Result:Click here